Heterocycle-substituted piperazino-dihydrothienopyrimidines

Compounds of formula 1

• wherein
• X denotes SO or SO2,
• R1 denotes H, C1-6-alkyl,
• R2 is H or a group selected from among C1-10-alkyl and C2-6-alkenyl, which may optionally be substituted by der optionally by one or more groups selected from halogen and C1-3-fluoroalkyl or which may optionally be substituted by one or more groups selected from among OR2.1, COOR2.1, CONR2.2R2.3, SR2.1, SO—R2.1, SO2—R2.1, C6-10-aryl, a het, a hetaryl, a mono- or bicyclic C3-10-cycloalkyl, CH2—NR2.2R2.3 and NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, halogen, OR2.1, oxo, CF3, CHF2, CH2F, C1-6-alkyl, C1-6-alkanol, C6-10-aryl, COOR2.1, CH2—NR2.2R2.3 and NR2.2R2.3,
• wherein R2.1 is H or a group selected from among C1-6-alkyl, C1-6-alkanol, C1-3-haloalkyl, mono- or bicyclic C3-10-cycloalkyl, C6-10-aryl-C1-6-alkylene, mono- or bicyclic hetaryl-C1-6-alkylene, het-C1-6-alkylene, C3-10-cycloalkyl-C1-6-alkylene, a mono- or bicyclic C6-10-aryl, a hetaryl and a het,
• which may optionally be substituted by one or more groups selected from among OH, O—(C1-3-alkyl), halogen, C1-6-alkyl and C6-10-aryl,
• while R2.2 and R2.3 independently of one another denote H or a group selected from among C1-6-alkyl, mono- or bicyclic C3-10 cycloalkyl, aryl-C1-6-alkylene, hetaryl-C1-6-alkylene, mono- or bicyclic C6-10-aryl, het, hetaryl, CO—NH2, CO—NHCH3, CO—N(CH3)2, SO2—(C1-C2-alkyl), CO—R2.1 and COOR2.1,
• which may optionally be substituted by one or more groups selected from among OH, halogen, C1-6-alkyl, C6-10-aryl and COOR2.1,
• while
• het is a three- to eleven-membered, mono- or bicyclic, saturated or partially saturated, optionally anellated or optionally bridged heterocycle, which contains 1, 2, 3 or 4 heteroatoms selected independently of one another from among N, S or O,
• and while
• hetaryl is a five- to eleven-membered, mono- or bicyclic, optionally anellated heteroaryl which contains 1, 2, 3 or 4 heteroatoms selected independently of one another from among N, S or O,
• and while
• cycloalkyl may be saturated or partially saturated,
• or
• R2 denotes a mono- or polycyclic C3-10 cycloalkyl, which may optionally be bridged one or more times by C1-3-alkyl groups and which may optionally be substituted by a group selected from among branched or unbranched C1-6-alkanol, C1-3-fluoroalkyl, C1-3-alkylene-OR2.1, COOR2.1, SO2—NR2.2—R2.3, het, C6-10-aryl, C6-10-aryl-C1-6-alkylene, hetaryl-C1-6-alkylene, mono- or bicyclic C3-10 cycloalkyl and NR2.2R2.3, which may optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, halogen, CF3, CHF2, CH2F, C6-10-aryl and NR2.2R2.3,
• or
• R2 denotes a mono- or polycyclic C6-10-aryl, which may optionally be substituted by OH, SH or halogen or by one or more groups selected from among OR2.1, COOR2.1, NR2.2—R2.3, CH2—NR2.2R2.3, C3-10-cycloalkyl, het, —C1-6-alkyl, C1-3-fluoroalkyl, C6-10-aryl-C1-6-alkylene, het-C1-6-alkylene, hetaryl-C1-6-alkylene, C6-10-aryl, SO2—CH3, SO2—CH2CH3 and SO2—NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, OR2.1, CF3, CHF2, CH2F, oxo, halogen, CF3, CHF2, CH2F, C1-6-alkyl, C6-10-aryl and NR2.2R2.3,
• or
• R2 denotes a group selected from among het and hetaryl, which may optionally be substituted by one or more groups selected from among halogen, OH, oxo, CF3, CHF2 and CH2F or by one or more groups selected from among OR2.1, C1-3-alkylene-OR2.1, SR2.1, SO—R2.1 and SO2—R2.1, COOR2.1, COR2.1, C1-6-alkanol, C3-10-cycloalkyl, C6-10-aryl, C6-10-aryl-C1-6-alkylene, hetaryl-C1-6-alkylene, het, hetaryl, C1-3-alkylene-OR2.1 and NR2.2R2.3, which may in turn optionally be substituted by one or more groups selected from among OH, OR2.1, oxo, halogen, CF3, CHF2, CH2F, C6-10-aryl and NR2.2R2.3,
• or wherein
• NR1R2 together denotes a heterocyclic four- to seven-membered ring which may optionally be bridged, which contains 1, 2 or 3 heteroatoms selected from among N, O and S and which may optionally be substituted by one or more groups selected from among OH, OR2.1, C1-3-alkylene-OR.1, oxo, halogen, C1-6-alkyl, C6-10-aryl, COOR2.1, CH2—NR2.2—COO—R2.1, CH2—NR2.2—CO—R2.1, CH2—NR2.2—CO—CH2—NR2.2R2.3, CH2—NR2.2—SO2—C1-3-alkyl, CH2—NR2.2—SO2—NR2.2R2.3, CH2—NR2.2—CO—NR2.2R2.3, CO—NR2.2R2.3, CH2—NR2.2R2.3 and NR2.2R2.3,
• and wherein
• R3 is a group selected from among a het and a hetaryl, which may optionally be substituted by one or more groups selected from among halogen, C1-3-fluoroalkyl, CN, OH, oxo, —O—R2.1, —COOR2.1, SO—R2.1, SO2—R2.1, C6-10-aryl, C1-3-alkylene-C6-10-aryl, —C1-3-alkylene-NR2.2R2.3, —NR2.2R2.3, a C3-10-cycloalkyl, a C1-3-alkylene-C3-10-cycloalkyl, a het, a hetaryl, C1-3-alkylene-hetaryl, and C1-3-alkylene-het, which may in turn optionally be substituted by one or more groups selected from among OH, halogen, —C1-3-fluoroalkyl, C6-10-aryl, —COO(C1-3-alkyl) and O—(C1-3-alkyl),
• and pharmacologically acceptable salts thereof.